License Grant Upon Exercise Clause Samples
License Grant Upon Exercise. If Licensee exercises one of its Commercial Options for a particular disease indication (after confirmation that the nominated disease indication is available as described in Section 2.1.3), effective only upon Licensor’s receipt of the amounts set forth in, within the period set forth in, Section 2.1.3.4 (the date on which the payments are received in full shall be deemed to be the “Grant Date” for such disease indication), subject to the terms and conditions of this Agreement, including the Retained Rights and including any Excluded Rights, Licensor will be deemed to have granted to Licensee an exclusive, sublicensable (as provided in Section 2.4 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license, under the Licensed Technology to make, have made, use, import, sell, and offer for sale Licensed Products solely in the Field for the Licensed Indication, including, for the avoidance of doubt, the right to conduct research and development, including conducting pre-clinical and clinical trials.
License Grant Upon Exercise. If Licensee exercises the Commercial Option for a particular Disease Indication, effective upon Licensor’s receipt of the notice and, if applicable, fee described in Section 2.3.1 (the “Grant Date” for such Disease Indication with respect to the applicable Specified Vector), subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor shall be deemed to have granted to Licensee a non-exclusive, sublicensable (as provided in Section 2.6 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license under the applicable Licensed Commercial Patents to make, have made, use, import, sell, and offer for sale Licensed Products using the Specified Vector solely in the Commercial Field of such Disease Indication, including, for the avoidance of doubt, the right to conduct research and development.
License Grant Upon Exercise. If Licensee exercises the Substitution Indication Option for a particular Additional Disease Indication, effective upon Licensor’s receipt of the notice described in Section 2.2.2 (the “Substitution Grant Date” for such Additional Disease Indication), subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor shall be deemed to have granted to Licensee an exclusive, sublicensable (as provided in Section 2.6 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license under the Licensed Patents to make, have made, use, import, sell, and offer for sale Licensed Products in the Commercial Field of such Additional Disease Indication, including, for the avoidance of doubt, the right to conduct research and development. For avoidance of doubt, the license granted pursuant to this Section 2.2.3 will be deemed granted on the Substitution Grant Date with respect to a particular Additional Disease Indication, solely with respect to the Commercial Field associated with Additional Disease Indication for which the Substitution Indication Option was exercised under this Section 2.2 and solely with respect to Licensed Products for the particular Additional Disease Indication.
License Grant Upon Exercise. Effective upon Licensor’s receipt of the notice and fee described in Section 2.2.1 above (the “Grant Date”), subject to the terms and conditions of this Agreement, Licensor shall be deemed to have granted Licensee an exclusive (except as provided in Section 2.3), non-transferable (except as provided in Section 11.2), royalty-bearing, worldwide right and license, with the right to grant sublicenses only as provided in Section 2.5, under the Licensed Patents to make, have made, use, import, sell, and offer for sale Licensed Products solely in the Selected Commercial Field.
License Grant Upon Exercise. If Licensee exercises the Indication Option for the Option Field by providing such written notice, effective upon Licensor’s receipt of the fee described in Section 3.4 (the “Grant Date” for the Option Field ), subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor shall be deemed to have granted to Licensee an exclusive, sublicensable (as provided in Section 2.5 only), nontransferable (except as provided in Section 10.2), royalty-bearing, worldwide license under the Licensed Patents to make, have made, use, import, sell, and offer for sale Licensed Products in the Option Field, including, for the avoidance of doubt, the right to conduct research and development.
License Grant Upon Exercise. If Licensee exercises a Program Option by providing the written notice set forth in Section 2.1.2 for a particular Licensed Program, effective upon Licensor’s receipt of the fee described in Section 3.2 (the “Grant Date” for the applicable Licensed Program), subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor shall be deemed to have granted to Licensee an exclusive (even as to Licensor), sublicensable (as provided in Section 2.6 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license to Licensor’s interest under the Licensed Technology to make, have made, use, import, sell, and offer for sale Licensed Products solely in the Field that are the subject of such Licensed Program, including, for the avoidance of doubt, the right to conduct research and development. For the avoidance of doubt, subject to the rights contained in Section 2.3, the license granted in this Section 2.1.3 does not include rights to any genes other than the Licensed Option Genes.
License Grant Upon Exercise. If Licensee exercises a Commercial Option, effective upon Licensor’s receipt of the notice and, the fee described in Section 2.2.1 (the “Grant Date” for the applicable Licensed Program), subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor shall be deemed to have granted to Licensee an exclusive, sublicensable (as provided in Section 2.5 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license under the Licensed Technology to make, have made, use, import, sell, and offer for sale Licensed Products in the Field that are the subject of the Licensed Program, including, for the avoidance of doubt, the right to conduct research and development.